173 related articles for article (PubMed ID: 27543313)
21. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.
Klanova M; Andera L; Brazina J; Svadlenka J; Benesova S; Soukup J; Prukova D; Vejmelkova D; Jaksa R; Helman K; Vockova P; Lateckova L; Molinsky J; Maswabi BC; Alam M; Kodet R; Pytlik R; Trneny M; Klener P
Clin Cancer Res; 2016 Mar; 22(5):1138-49. PubMed ID: 26467384
[TBL] [Abstract][Full Text] [Related]
22. ID3 mutations are recurrent events in double-hit B-cell lymphomas.
Gebauer N; Bernard V; Feller AC; Merz H
Anticancer Res; 2013 Nov; 33(11):4771-8. PubMed ID: 24222112
[TBL] [Abstract][Full Text] [Related]
23. The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond.
Monaco G; Vervliet T; Akl H; Bultynck G
Cell Mol Life Sci; 2013 Apr; 70(7):1171-83. PubMed ID: 22955373
[TBL] [Abstract][Full Text] [Related]
24. BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth.
Deng J; Park D; Wang M; Nooka A; Deng Q; Matulis S; Kaufman J; Lonial S; Boise LH; Galipeau J; Deng X
Oncotarget; 2016 May; 7(19):27753-63. PubMed ID: 27049723
[TBL] [Abstract][Full Text] [Related]
25. BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition.
Gabellini C; De Luca T; Trisciuoglio D; Desideri M; Di Martile M; Passeri D; Candiloro A; Biffoni M; Rizzo MG; Orlandi A; Del Bufalo D
Carcinogenesis; 2013 Nov; 34(11):2558-67. PubMed ID: 23836782
[TBL] [Abstract][Full Text] [Related]
26. The Bcl-2 family: structures, interactions and targets for drug discovery.
Kvansakul M; Hinds MG
Apoptosis; 2015 Feb; 20(2):136-50. PubMed ID: 25398535
[TBL] [Abstract][Full Text] [Related]
27. Puma(*)Mcl-1 interaction is not sufficient to prevent rapid degradation of Mcl-1.
Mei Y; Du W; Yang Y; Wu M
Oncogene; 2005 Nov; 24(48):7224-37. PubMed ID: 16007132
[TBL] [Abstract][Full Text] [Related]
28. Insights into the multistep transformation process of lymphomas: IgH-associated translocations and tumor suppressor gene mutations in clonally related composite Hodgkin's and non-Hodgkin's lymphomas.
Schmitz R; Renné C; Rosenquist R; Tinguely M; Distler V; Menestrina F; Lestani M; Stankovic T; Austen B; Bräuninger A; Hansmann ML; Küppers R
Leukemia; 2005 Aug; 19(8):1452-8. PubMed ID: 15973455
[TBL] [Abstract][Full Text] [Related]
29. Functional dissection of Bfl-1, a Bcl-2 homolog: anti-apoptosis, oncogene-cooperation and cell proliferation activities.
D'Sa-Eipper C; Chinnadurai G
Oncogene; 1998 Jun; 16(24):3105-14. PubMed ID: 9671389
[TBL] [Abstract][Full Text] [Related]
30. Interaction of E1B 19K with Bax is required to block Bax-induced loss of mitochondrial membrane potential and apoptosis.
Han J; Modha D; White E
Oncogene; 1998 Dec; 17(23):2993-3005. PubMed ID: 9881701
[TBL] [Abstract][Full Text] [Related]
31. Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain.
Iyer D; Vartak SV; Mishra A; Goldsmith G; Kumar S; Srivastava M; Hegde M; Gopalakrishnan V; Glenn M; Velusamy M; Choudhary B; Kalakonda N; Karki SS; Surolia A; Raghavan SC
FEBS J; 2016 Sep; 283(18):3408-37. PubMed ID: 27444341
[TBL] [Abstract][Full Text] [Related]
32. Mutations of the BIK gene in human peripheral B-cell lymphomas.
Arena V; Martini M; Luongo M; Capelli A; Larocca LM
Genes Chromosomes Cancer; 2003 Sep; 38(1):91-6. PubMed ID: 12874789
[TBL] [Abstract][Full Text] [Related]
33. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
Kim S; Nam SJ; Kwon D; Kim H; Lee E; Kim TM; Heo DS; Park SH; Kim CW; Jeon YK
BMC Cancer; 2016 Jun; 16():363. PubMed ID: 27286976
[TBL] [Abstract][Full Text] [Related]
34. C-MYC and BCL2 translocation frequency in diffuse large B-cell lymphomas: A study of 97 patients.
Akkaya B; Salim O; Akkaya H; Ozcan M; Yucel OK; Erdem R; Iltar U; Undar L
Indian J Pathol Microbiol; 2016; 59(1):41-6. PubMed ID: 26960633
[TBL] [Abstract][Full Text] [Related]
35. Regulation of mitochondrial metabolism: yet another facet in the biology of the oncoprotein Bcl-2.
Krishna S; Low IC; Pervaiz S
Biochem J; 2011 May; 435(3):545-51. PubMed ID: 21486225
[TBL] [Abstract][Full Text] [Related]
36. Contribution of membrane localization to the apoptotic activity of PUMA.
Yee KS; Vousden KH
Apoptosis; 2008 Jan; 13(1):87-95. PubMed ID: 17968660
[TBL] [Abstract][Full Text] [Related]
37. Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
Scarfò L; Ghia P
Immunol Lett; 2013; 155(1-2):36-9. PubMed ID: 24095849
[TBL] [Abstract][Full Text] [Related]
38. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4.
Huang DC; Adams JM; Cory S
EMBO J; 1998 Feb; 17(4):1029-39. PubMed ID: 9463381
[TBL] [Abstract][Full Text] [Related]
39. MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.
Wenzel SS; Grau M; Mavis C; Hailfinger S; Wolf A; Madle H; Deeb G; Dörken B; Thome M; Lenz P; Dirnhofer S; Hernandez-Ilizaliturri FJ; Tzankov A; Lenz G
Leukemia; 2013 Jun; 27(6):1381-90. PubMed ID: 23257783
[TBL] [Abstract][Full Text] [Related]
40. Loss-of-function of Fbxo10, encoding a post-translational regulator of BCL2 in lymphomas, has no discernible effect on BCL2 or B lymphocyte accumulation in mice.
Masle-Farquhar E; Russell A; Li Y; Zhu F; Rui L; Brink R; Goodnow CC
PLoS One; 2021; 16(4):e0237830. PubMed ID: 33914737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
